Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun 25;135(26):2329-2330.
doi: 10.1182/blood.2020005876.

NLP Hodgkin lymphoma: can we get away with less?

Alison J Moskowitz  1
Affiliations
Comment

NLP Hodgkin lymphoma: can we get away with less?

Alison J Moskowitz. Blood. .
No abstract available

PubMed Disclaimer

Figures

None
Treatment choices for early-stage NLPHL.
See this image and copyright information in PMC

Comment on

  • Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
    Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang R, Dickinson M, Ng AK, Roberts KB, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis SA, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani RH, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT. Binkley MS, et al. Blood. 2020 Jun 25;135(26):2365-2374. doi: 10.1182/blood.2019003877. Blood. 2020. PMID: 32211877

References

    1. Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020;135(26):2365–2374. - PubMed
    1. Nogová L, Reineke T, Brillant C, et al. German Hodgkin Study Group Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26(3):434–439. - PubMed
    1. Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: A report from the German Hodgkin Study Group. J Clin Oncol. 2020;38(7):698–705. - PubMed
    1. Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group. J Clin Oncol. 2016;34(20):2372–2379. - PMC - PubMed
    1. Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019;133(20):2121–2129. - PMC - PubMed